



MEDICAL JOURNAL OF WESTERN INDIA

THE OFFICIAL PUBLICATION OF RESEARCH SOCIETY OF BJMC AND SGH, PUNE

WEBSITE: www.mjwi.org

ISSN NO.: 0972-9798

EISSN No.: 0972-9798

CLINICAL

A FATAL CASE OF SINONASAL INVASIVE PENICILLIOSIS WITH DIFFUSE LARGE B-CELL LYMPHOMA

[DR ANITA BASAVARAJ](#)¹, [DR YAGNESH D DOSHI](#)^{2*},

1) GOVERNMENT MEDICAL COLLEGE AND HOSPITAL MIRAJ - PROFESSOR AND HEAD, DEPT OF GENERAL MEDICINE, GMCH MIRAJ

2) GOVERNMENT MEDICAL COLLEGE AND HOSPITAL, MIRAJ. - OLD IHR HOSTEL, GMC MIRAJ

* means Correspondance Author

ARTICLE INFO

Article history:

Date of Web Publication 31 Mar 2022

Date of Receipt: 31 Mar 2022

Date of Acceptance: 18 Apr 2022

Date of Publication: 01 Jan 1970

Article No: 181

ABSTRACT

We report a case of Sinonasal Penicillium species with multiorgan dysfunction syndrome in a 64 year old female synchronously diagnosed with Diffuse Large B-Cell Lymphoma(DLBCL) having Diabetes Mellitus(DM) and Hypertension(HTN) admitted in our tertiary care hospital as a COVID 19 Suspect. Sinonasal Penicillium invasion is a rare, opportunistic, potentially fatal and acute invasive infection mostly affecting people with hematological malignancies. In this patient underlying DLBCL and Diabetes Mellitus could be the likely cause for Penicillium infection suggesting the need for vigilance in hospitalized patients with prompt diagnosis and timely management.

KEYWORDS

COVERING

To,

The Editor

Subject : Submission of Manuscript for publication

Respected Sir,

We intend to publish an article

entitled "A FATAL CASE OF SINONASAL INVASIVE PENICILLIOSIS WITH DIFFUSE LARGE B-CELL LYMPHOMA" in your journal as a Case Report.

On behalf of all the contributors I will act and guarantor and will correspond with the journal from this point onward.

Prior publication NONE

Support NA

Conflicts of interest NONE

Permissions NA

We hereby transfer, assign, or otherwise convey all copyright ownership, including any and all rights incidental thereto, exclusively to the journal, in the event that such work is published by the journal.

Thanking you,

Yours' sincerely,

Signature

FIRST AUTHOR - DR ANITA
BASAVARAJ

CORRESPONDING AUTHOR

DR YAGNESH D DOSHI

E-mail -

anita.basavaraj@rediffmail.com

Contributors' form /COPYRIGHT FORM

Journal Title: A FATAL CASE OF SINONASAL
INVASIVE PENICILLIOSIS WITH DIFFUSE LARGE B-CELL
LYMPHOMA

I/we certify that I/we have participated sufficiently in the intellectual content, conception

and design of this work or the analysis and interpretation of the data (when applicable), as well as the writing of the manuscript, to take public responsibility for it and have agreed to have my/our name listed as a contributor. I/we believe the manuscript represents valid work. Each author confirms they meet the criteria for authorship as established by the ICMJE. Neither this manuscript nor one with substantially similar content under my/our authorship has been published or is being considered for publication elsewhere, except as described in the covering letter. I/we certify that all the data collected during the study is presented in this manuscript and no data from the study has been or will be published separately. I/we attest that, if requested by the editors, I/we will provide the data/information or will cooperate fully in obtaining and providing the data/information on which the manuscript is based, for examination by the editors or their assignees. Financial interests, direct or indirect, that exist or may be perceived to exist for individual contributors in connection with the content of this paper have been disclosed in the cover letter. Sources of outside support of the project are named in the cover letter.

I/We hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership, including any and all rights incidental there to, exclusively to the Journal, in the event that such work is published by the Journal. The Journal shall own the work, including 1) copyright; 2) the right to grant permission to republish the article in whole or in part, with or without fee; 3) the right to produce preprints or reprints and translate into languages other than English for sale or free distribution; and 4) the right to republish the work in a collection of articles in any other mechanical or electronic format.

We give the rights to the corresponding author to make necessary changes as per the request of the journal, do the rest of the correspondence on our behalf and he/she will act as the guarantor for the manuscript on our behalf.

All persons who have made substantial contributions to the work reported in the manuscript, but who are not contributors, are named in the Acknowledgment and have given me/us their written permission to be named. If I/we do not include an Acknowledgment that means I/we have not received substantial contributions from non-

contributors and no contributor has been omitted.

Name Signature Date signed

1. DR ANITA BASAVARAJ 31/03/2022

2. DR YAGNESH D DOSHI 31/03/2022

Type of article: Case Report

Title of the article:

Running title : A FATAL CASE OF SINONASAL INVASIVE PENICILLIOSIS WITH DIFFUSE LARGE B-CELL LYMPHOMA

Contributors

1. DR ANITA BASAVARAJ

Professor and Head, Dept of General Medicine, GMC Miraj.

Department(s) and institution(s)

Corresponding Author: 2. DR YAGNESH D DOSHI

Total number of pages: 10

Total number of photographs: 7

Word counts

for abstract: 90

Source(s) of support: NONE

Presentation at a meeting: NONE

Organisation NA

Place NA

Date NA

Conflicting Interest (If present, give more details): NONE

1. Acknowledgement: Dept. Of Microbiology, Government Medical College, Miraj.

2. Dept. Of Radiology, Government Medical College, Miraj.

A FATAL CASE OF SINONASAL INVASIVE PENICILLIOSIS WITH

DIFFUSE LARGE B-CELL LYMPHOMA

Dr. Anita Basavaraj **1**, Dr. Yagnesh D Doshi **2**

3. Professor and Head, Dept of General Medicine, Government Medical College, Miraj.

4. Junior Resident, Dept of General Medicine, Government Medical College, Miraj.

ABSTRACT

We report a case of Sinonasal *Penicillium* species with multiorgan dysfunction syndrome in a 64 year old female synchronously diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL) having Diabetes Mellitus (DM) and Hypertension (HTN) admitted in our tertiary care hospital as a COVID 19 Suspect. Sinonasal *Penicillium* invasion is a rare, opportunistic, potentially fatal and acute invasive infection mostly affecting people with hematological malignancies. In this patient underlying DLBCL and Diabetes Mellitus could be the likely cause for *Penicillium* infection suggesting the need for vigilance in hospitalized patients with prompt diagnosis and timely management.

KEYWORDS

Penicillium, DLBCL, DM, COVID 19, Amphotericin B.

INTRODUCTION

Penicillium species, in spite of being the most common fungi in the environmental surroundings, are often considered as non-pathogenic to human beings.¹ However they can be a virulent pathogen and may cause death in immunocompromised host.² Lungs, skin, nasal sinuses and brain constitute the major site of *penicillium* infection. A dysfunctional immune response along with an impaired mucosal barrier may predispose to *penicilliosis*. Use of corticosteroids along with these co existing risk factors is also a common cause for the disease. ^{3,4} Other predisposing conditions may include prolonged neutropenia, diabetes mellitus, haematological malignancy, hematopoietic stem cell

transplantation or trauma. Immunocompromised state along with long term use of deferoxamine, long-term voriconazole prophylaxis or undergoing solid organ transplantation, or with iron overload also constitutes a major cause for *penicillium* infection.^{5,6}

Penicillium spp. although considered as non pathogenic, are occasional causes of infection in human beings and the resulting infection is known as *penicilliosis*. *Penicillium* species has been commonly isolated from patients with otomycosis, keratitis, urinary tract infections, endophthalmitis, pneumonia, endocarditis, necrotizing esophagitis, peritonitis.

To add to its infectious potential, *Penicillium verrucosum* also produces a mycotoxin known as ochratoxin A, which is carcinogenic and nephrotoxic.⁷ *Penicillium marneffei* infection known as *aspergilliosis marneffei*, is commonly acquired via inhalational route in immunocompromised hosts causing pulmonary infection later complicated by fungemia and disseminated infection. Later on usually involves the bones, liver, spleen and lymphatic system. Acne-like skin papules and lesions are observed during the course of illness on face, extremities and trunk. *Penicilliosis marneffei* infection along with immunocompromised or other risk factors is often a fatal disease.^{8,9}

CASE REPORT

We report a case of a 64 year old female from rural southern Maharashtra, a known case of hypertension and diabetes mellitus who was admitted as a suspected case of COVID 19 which came RTPCR negative, however was later diagnosed as Non Hodgkin Lymphoma - DLBCL, along with *penicilliosis* and multi organ dysfunction syndrome during the course of her hospital stay.

In September 2021 she presented to our tertiary care hospital with complaints of generalized weakness since past 1 month, dry cough since past couple of weeks and abdominal pain since few days. She also had history of intermittent moderate grade fever since a week for which she was admitted as a COVID 19 suspect considering the COVID pandemic and her RTPCR was sent. She had taken both doses of COVID vaccination. On admission she was afebrile, her pulse was regular 80 per minute and blood pressure was controlled on oral medications. Her random blood sugar was 220 mg/dl and had blood oxygen saturation levels of 92% on room air. She was started on oxygen by nasal prongs at 23 lit/minute, intravenous fluids, empirically on inj. ceftriaxone 1gm q12h, inj. pantoprazole, insulin, inj. paracetamol and other supportive care.

On admission her investigations were: -

FIGURE 4 CT CHEST

Further her Bone Marrow Aspirate and Biopsy was done and reports were awaited. She was started on injection piperacillin + tazobactam and injection Levofloxacin and other supportive care. Over the next 2-3 days she was gradually tapered off O2 and was maintaining blood oxygen saturation levels around 96% on room air. Further on day 10 of admission she started complaining of difficulty in breathing with nasal congestion associated with headache and facial pain. MRI Orbit/Brain/PNS was done which showed heterogeneously enhancing soft tissue in bilateral frontal, ethmoidal and sphenoid sinus and was asked to rule out mucormycosis. Further nasal endoscopy was done along with sinus mucosal biopsy. The sample was sent for KOH mounts and culture sensitivity tests.

FIGURE 5 CT BRAIN

KOH mount reports were negative for fungal growth. She was empirically started on injection Amphotericin B Deoxycholate. Sinus mucosal samples were also sent for microscopy and culture sensitivity tests. Bone marrow aspirate and biopsy was sent for routine examination and immunohistochemistry.

She was transfused with 1 unit of whole blood. Her peripheral smear was unremarkable and dengue profile/Weil Felix test/ Widal tests were negative. Urine routine tests were within normal limits. Chest x-ray was suggestive of bilateral lower zone heterogenous opacities with perihilar shadows as shown in figure A. Her sputum and blood cultures were obtained before initiation of antibiotics. Later her culture reports didn't show any microbial growth and thereby she was continued on the same line of management.

On day 5 of admission, she started complaining of increasing severity of abdominal pain associated with per rectal bleed. Her USG abdomen was suggestive of moderate hepatosplenomegaly and multiple enlarged lymph nodes. Her blood counts were repeated which showed hemoglobin of 4.7g/dl, TLC 4860 cells/mm³ and platelet count 25000. In view of ongoing per rectal bleed she was transfused with 4 units of random donor platelet and was given a total of 3 units of whole blood transfusion during her course of hospital stay. Her CECT Abdomen and Pelvis was suggestive of hepatosplenomegaly with abdominal lymphadenopathy with renal deposits.

FIGURE 3 CT ABDOMEN

Unfortunately patient started deteriorating haemodynamically and repeat blood reports showed haemoglobin 5g/dl, platelet count 29000/mm³, TLC 9000/mm³, serum creatinine 2.6mg%, blood urea levels 152 mg%, total bilirubin 6.8 (direct -3.4), SGOT-267, SGPT-118, ALP-510. She was then shifted to intensive care unit in view of hypotension and started on inotropic supports. Inj. Amphotericin B was withheld due to acute kidney injury and decreasing eGFR and MODS. Hemodialysis could not be done due to persistent hypotension inspite of inotropic support and finally she succumbed to death.

Later, her bone marrow reports were - MCV 78.2fL, MCH 25.7pg, MCHC 32.8 g/dL, WBC 5800/ul, platelet count 164000/ul. Atypical cells / Blasts 31 %, Neutrophils 19 %, Promyelocytes 02%, Monocytes 04 %, Myelocytes 08 %, Eosinophils 02 %, Metamyelocytes

06 %, Lymphocytes 20 %, Band forms 08 %, Erythroid precursors 20 % . IHC showed CD20, CD79a, BCL-2, MUM 1 Positive with Ki67 proliferative index of 50-60%; Features consistent with bone marrow involvement by Diffuse Large B-cell Lymphoma- NonGerminalcentre type.

Sphenoid Sinus Mucosal biopsy - culture and microscopy reports further showed penicillium spp. growth.

Figure 6 :- Greenish Mycelial colonies of *Penicillium* species on SDA media.

Figure 7 :- Paintbrush like appearance of *Penicillium* species along with chains of conidia.

DISCUSSION

Pulmonary infections with fungi, including *Penicillium* species, are associated with much higher mortality rates in patients with nosocomial infections or infections complicating organ failure.¹⁰ *Penicillium* species can cause opportunistic infections.¹¹ Some patients with infections caused by *Penicillium* species have died despite treatment with ketoconazole, amphotericin B, or itraconazole.¹²

Penicillium-like fungi are commonly recovered from clinical samples, in routine hospital air surveys and in clinical practice, and are often encountered as airborne contaminants of culture specimens.^{13,14} Often *Penicillium* species isolated from samples of non-AIDS patients are discarded as environmental contaminants and considered nonpathogenic. However, in immunosuppressed patients, non-marneffeii species are being increasingly recognized as emerging opportunistic pathogens causing invasive fungal infections worldwide, with most reports involving *P.citrinum*, *P.digitatum*, and *P.chrysogenum* (Table 1)¹⁵⁻²⁶.

acute lymphoblastic leukemia; AML, acute Myeloid leukemia; MM, multiple myeloma; IFI, invasive fungal infection; BAL, bronchoalveolar lavage; AMB, amphotericin B deoxycholate; FCZ, fluconazole; PCZ, posaconazole; CSP, caspofungin; VCZ, voriconazole; ITZ, itraconazole; 5-FC, 5-flucytosine; MCZ, miconazole; DLBCL, Diffuse Large B Cell Lymphoma; NA, not available.

To summarise, as per the review, *P.chrysogenum* is considered to be the most prevalent species causing infection in immunosuppressed patients causing systemic and disseminated disease with invasive pulmonary infection. Conventional phenotypic methods may be not enough and difficult to confirm a diagnosis of Penicilliosis. Identification at the species level yet is challenging.²⁷

With the Standard treatment for non-marneffeii species not yet been established and antifungal susceptibility data for clinically available antifungal agents and treatment options for infections caused by *Penicillium* species also being poorly understood, only data from *T.marneffeii* has been published. In a recent study of 118 clinical isolates, (mainly from the respiratory tract/human bronchoalveolar lavage) terbinafine (TRB) and the echinocandins showed the best in vitro activity against *Penicillium* species with MIC < 0.03 µg/mL for TRB, azoles revealed variable activity with MIC ranges of 0.5 µg/mL for posaconazole and 2 µg/mL for voriconazole and itraconazole, 0.06 µg/mL for caspofungin and anidulafungin, and 0.125 for micafungin; amphotericin B showed intermediate activity with MIC of 2 µg/mL.²⁸ In conclusion, of importance, if normally sterile sites are involved in sampling, *Penicillium* spp. isolates especially in an immunocompromised host should not be disregarded without a thorough investigation.

TABLE 2:- Showing cases of penicillium species infection in haematological malignancies in various studies conducted.

BMT, bone marrow transplant; ALL,

Funding

This case study received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Informed Consent was taken of patient's relative.

Acknowledgments:

5. Dept. Of Microbiology, Government Medical College, Miraj.
6. Dept. Of Radiology, Government Medical College, Miraj.

Conflicts of Interest: The authors declare no conflict of interest. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Centre for Disease Control and Prevention.

10. Bartoletti M., Pascale R., Cricca M., Rinaldi M., Maccaro A., Bussini L., Fornaro G., Tonetti T., Pizzilli G., Francalanci E., et al. Epidemiology of Invasive Pulmonary Aspergillosis Among Intubated Patients With COVID-19: A Prospective Study. *Clin. Infect. Dis.* 2020 doi: 10.1093/cid/ciaa1065.
11. Verweij P.E., Rijnders B.J.A., Brüggemann R.J.M., Azoulay E., Bassetti M., Blot S., Calandra T., Clancy C.J., Cornely O.A., Chiller T., et al. Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: An expert opinion. *Intensive Care Med.* 2020;46:1524-1535. doi: 10.1007/s00134020-06091-6.
12. Fishman AP, Elias JA, Fishman JA, Grippi MA, Senior RM, Pack AI, Chamilos G, Kontoyiannis DP Aspergillus, Candida, and other opportunistic mould infections of the lung. In: Fishman AP, Elias JA, Fishman JA, Grippi MA, Senior RM, Pack AI, editors. *Fishman's pulmonary diseases and disorders*, 4th edition, volume 2. New York: McGraw-Hill; 2008;2291-2326.
13. Pitt, J. I. 2000. Toxigenic fungi: which are important? *Med Mycol.* 38:17-22.
14. Cheng, N. C., W. W. Wong, C. P. Fung, and C. Y. Liu. 1998. Unusual pulmonary manifestations of disseminated *Penicillium marneffei* infection in three AIDS patients. *Med Mycol.* 36:429-432.
15. Singh, P. N., K. Ranjana, Y. I. Singh, K. P. Singh, S. S. Sharma, M. Kulachandra, Y. Nabakumar, A. Chakrabarti, A. A. Padhye, L. Kaufman, and L. Ajello. 1999. Indigenous disseminated *Penicillium marneffei* infection in the state of Manipur, India: Report of four autochthonous cases. *J Clin Microbiol.* 37:2699-2702.
16. Chen KY, Ko SC, Hsueh PR, Luh KT, Yang PC: Pulmonary fungal infection. Emphasis on microbiological spectra, patient outcome and prognostic factors. *Chest.* 2001, 120: 177-10.1378/chest.120.1.177.
17. Mok T, Koehler AP, Yu MY, Ellis DH, Johnson PJ, Wickham NW: Fatal *Penicillium citrinum* pneumonia with pericarditis in a patient with acute leukemia. *J Clin Microbiol.* 1997, 35: 2654-2656.

REFERENCES

7. Raper KB, Thom C: *Penicillium digitatum*. A Manual of the Penicillia. 1968, New York: Hafner Publ. Co, 386-392.
8. Mok T, Koehler AP, Yu MY, Ellis DH, Johnson PJ, Wickham NW: Fatal *Penicillium citrinum* pneumonia with pericarditis in a patient with acute leukemia. *J Clin Microbiol.* 1997, 35: 2654-2656.
9. Lyratzopoulos G, Ellis M, Nerringer R, Denning DW: Invasive infection due to *Penicillium* species other than *P. marneffei*. *J Infection.* 2005, 45: 184-207.
10. Pfaller MA, Messer SA, Hollis RJ, Jones RN, SENTRY Participants Group: Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates and *Aspergillus* spp. and other filamentous fungi: report from SENTRY antimicrobial surveillance program, 2000. *Antimicrob Agents Chemother.* 2002, 46: 1032-1037. 10.1128/AAC.46.4.1032-1037.2002.
19. da Silva, A., J. C. Porto, J. L. Da Silva, K. F. Morais, F. A.Coelho, Lopes T. de Sousa, et al. 2016. Evaluation

- of disinfectants for elimination of fungal contamination of patient beds in a reference hospital in Piauí, Brazil. *Environ. Monit. Assess.* 188:644.
20. Okten, S., and A. Asan. 2012. Airborne fungi and bacteria in indoor and outdoor environment of the Pediatric Unit of Edirne Government Hospital. *Environ. Monit. Assess.* 184:1739–1751
 21. Mok, T., A. P. Koehler, M. Y. Yu, D. H. Ellis, P. J. Johnson, and N. W. Wickham. 1997. Fatal *Penicillium citrinum* pneumonia with pericarditis in a patient with acute leukemia. *J. Clin. Microbiol.* 35:2654–2656.
 22. Mori, T., M. Matsumura, T. Kohara, Y. Watanabe, T. Ishiyama, Y. Wakabayashi, et al. 1987. A fatal case of pulmonary penicilliosis. *Jpn. J. Med. Mycol.* 28:341–348.
 23. Breton, P., P. Germaud, O. Morin, A. F. Audouin, N. Milpied, and J. L. Harousseau. 1998. Rare pulmonary mycoses in patients with hematologic diseases. *Rev. Pneumol. Clin.* 54:253–257.
 24. Shamberger, R. C., H. J. Weinstein, H. E. Grier, and R. H. Levey. 1985. The surgical management of fungal pulmonary infections in children with acute myelogenous leukemia. *J. Pediatr. Surg.* 20:840–844.
 25. Shokouhi, S., S. Tehrani, and M. Hemmatian. 2016. Mixed pulmonary infection with *Penicillium notatum* and *Pneumocystis jirovecii* in a patient with acute myeloid leukemia. *Tanaffos* 15:53–56.
 26. Chowdhary, A., S. Kathuria, K. Agarwal, N. Sachdeva, P. K. Singh, S. Jain, et al. 2014. Voriconazole-resistant *Penicillium oxalicum*: an emerging pathogen in immunocompromised hosts. *Open Forum Infect. Dis.* 1:ofu029.
 27. Huang, S. N. 1963. Acute disseminated penicilliosis. Report of a case and review of the pertinent literature. *Am. J. Clin. Pathol.* 39:167–174.
 28. de la Camara, R., I. Pinilla, E. Muñoz, B. Buendía, J. L. Steegmann, and J. M. Fernández-Ramírez. 1996. *Penicillium brevicompactum* as the cause of a necrotic lung ball in an allogeneic bone marrow transplant recipient. *Bone Marrow Transplant.* 18:1189–1193.
 29. Atalay, A., A. N. Koc, G. Akyol, N. Cakir, L. Kaynar, and A. Ulu-Kilic. 2016. Pulmonary infection caused by *Talaromyces purpurogenus* in a patient with multiple myeloma. *Infez. Med.* 24:153–157
 30. Successful treatment of pulmonary invasive fungal infection by *Penicillium nonmarneffii* in lymphoblastic lymphoma: case report and literature review. *Label Ramirez* 1,2, Alicia Hidron 1,3 & Ricardo Cardona
 31. Geltner, C., C. Lass-Floer, H. Bonatti, L. Müller, and I. Stelzmueller. 2013. Invasive pulmonary mycosis due to *Penicillium chrysogenum*: a new invasive pathogen. *Transplantation* 95:e21–e23.
 32. Swoboda-Kopec, E., M. M. Wroblewska, A. Rokosz, and M. Luczak. 2003. Mixed bloodstream infection with *Staphylococcus aureus* and *Penicillium chrysogenum* in an immunocompromised patient: case report and review of the literature. *Clin. Microbiol. Infect.* 9:1116–1117.
 33. Ghannoum, M. A., R. J. Jurevic, P. K. Mukherjee, F. Cui, M. Sikaroodi, A. Naqvi, et al. 2010. Characterization of the oral fungal microbiome (mycobiome) in healthy individuals. *PLoS Pathog.* 6:e1000713.
 34. Guevara-Suarez, M., D. A. Sutton, J. F. Cano-Lira, D. Garcia, A. Martin-Vicente, N. Wiederhold, et al. 2016. *Penicillium*-like fungi from clinical samples in the USA and their antifungal susceptibility. *J. Clin. Microbiol.* 54:2155–2161. ©2018 The Authors. *Clinical Case Reports* published by John Wiley & Sons Ltd. 11571. Ramirez et al. Penicilliosis and immunosuppression.

Acknowledgement

1. Dept. Of Microbiology, Government Medical College, Miraj. 2. Dept. Of Radiology, Government Medical College, Miraj.

Conflict of Interest

Financial Support and Sponsorship

NONE

Open Access Statement

The Research Society was founded for sharing and propagating the research activity and knowledge gained through it, for the betterment of the patient care and society at large.

Keeping this fundamentals in mind the journal has an open access policy.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

References

1. Raper KB, Thom C: *Penicillium digitatum*. A Manual of the Penicillia. 1968, New York: Hafner Publ. Co, 386-392.
2. Mok T, Koehler AP, Yu MY, Ellis DH, Johnson PJ, Wickham NW: Fatal *Penicillium citrinum* pneumonia with pericarditis in a patient with acute leukemia. *J Clin Microbiol.* 1997, 35: 2654-2656.
3. Lyratzopoulos G, Ellis M, Nerringer R, Denning DW: Invasive infection due to *Penicillium* species other than *P. marneffei*. *J Infection.* 2005, 45: 184-207.
4. Bartoletti M., Pascale R., Cricca M., Rinaldi M., Maccaro A., Bussini L., Fornaro G., Tonetti T., Pizzilli G., Francalanci E., et al. Epidemiology of Invasive Pulmonary Aspergillosis Among Intubated Patients With COVID-19: A Prospective Study. *Clin. Infect. Dis.* 2020 doi: 10.1093/cid/ciaa1065.
5. Verweij P.E., Rijnders B.J.A., Brüggemann R.J.M., Azoulay E., Bassetti M., Blot S., Calandra T., Clancy C.J., Cornely O.A., Chiller T., et al. Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: An expert opinion. *Intensive Care Med.* 2020;46:1524-1535. doi: 10.1007/s00134020-06091-6.
6. Fishman AP, Elias JA, Fishman JA, Grippi MA, Senior RM, Pack AI, Chamilos G, Kontoyiannis DP *Aspergillus*, *Candida*, and other opportunistic mould infections of the lung. In: Fishman AP, Elias JA, Fishman JA, Grippi MA, Senior RM, Pack AI, editors. *Fishman's pulmonary diseases and disorders*, 4th edition, volume 2. New York: McGraw-Hill; 2008;2291-2326.
7. Pitt, J. I. 2000. Toxigenic fungi: which are important? *Med Mycol.* 38:17-22.
8. Cheng, N. C., W. W. Wong, C. P. Fung, and C. Y. Liu. 1998. Unusual pulmonary manifestations of disseminated *Penicillium marneffei* infection in three AIDS patients. *Med Mycol.* 36:429-432.
9. Singh, P. N., K. Ranjana, Y. I. Singh, K. P. Singh, S. S. Sharma, M. Kulachandra, Y. Nabakumar, A. Chakrabarti, A. A. Padhye, L. Kaufman, and L. Ajello. 1999. Indigenous disseminated *Penicillium marneffei* infection in the state of Manipur, India: Report of four autochthonous cases. *J Clin Microbiol.* 37:2699-2702.
10. Chen KY, Ko SC, Hsueh PR, Luh KT, Yang PC: Pulmonary fungal infection. Emphasis on microbiological spectra, patient outcome and prognostic factors. *Chest.* 2001, 120: 177-10.1378/chest.120.1.177.
11. Mok T, Koehler AP, Yu MY, Ellis DH, Johnson PJ, Wickham NW: Fatal *Penicillium citrinum* pneumonia with pericarditis in a patient with acute leukemia. *J Clin Microbiol.* 1997, 35: 2654-2656.
12. Pfaller MA, Messer SA, Hollis RJ, Jones RN, SENTRY Participants Group: Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates and *Aspergillus* spp. and other filamentous fungi: report from SENTRY antimicrobial surveillance program, 2000. *Antimicrob Agents Chemother.* 2002, 46: 1032-1037. doi:10.1128/AAC.46.4.1032-1037.2002.
13. da Silva, A., J. C. Porto, J. L. Da Silva, K. F. Morais, F. A. Coelho, Lopes T. de Sousa, et al. 2016. Evaluation of disinfectants for elimination of fungal contamination of patient beds in a reference hospital in Piauí, Brazil. *Environ. Monit. Assess.* 188:644.
14. Okten, S., and A. Asan. 2012. Airborne fungi and bacteria in indoor and outdoor environment of the Pediatric Unit of Edirne Government Hospital. *Environ. Monit. Assess.* 184:1739-1751.
15. Mok, T., A. P. Koehler, M. Y. Yu, D. H. Ellis, P. J. Johnson, and N. W. Wickham. 1997. Fatal *Penicillium citrinum* pneumonia with pericarditis in a patient with acute leukemia. *J. Clin. Microbiol.* 35:2654-2656.
16. Mori, T., M. Matsumura, T. Kohara, Y. Watanabe, T. Ishiyama, Y. Wakabayashi, et al. 1987. A fatal case of pulmonary penicilliosis. *Jpn. J. Med. Mycol.* 28:341-348.
17. Breton, P., P. Germaud, O. Morin, A. F. Audouin, N. Milpied, and J. L. Harousseau. 1998. Rare pulmonary mycoses in patients with hematologic diseases. *Rev. Pneumol. Clin.* 54:253-257.
18. Shamberger, R. C., H. J. Weinstein, H. E. Grier, and R. H. Levey. 1985. The surgical management of fungal pulmonary infections in children with acute myelogenous leukemia. *J. Pediatr. Surg.* 20:840-844.
19. Shokouhi, S., S. Tehrani, and M. Hemmatian. 2016. Mixed pulmonary infection with *Penicillium notatum* and *Pneumocystis jirovecii* in a patient with acute myeloid leukemia. *Tanaffos* 15:53-56.
20. Chowdhary, A., S. Kathuria, K. Agarwal, N. Sachdeva, P. K. Singh, S. Jain, et al. 2014. Voriconazole-resistant *Penicillium oxalicum*: an emerging pathogen in immunocompromised hosts. *Open Forum Infect. Dis.* 1:ofu029.
21. Huang, S. N. 1963. Acute disseminated penicilliosis. Report of a case and review of the pertinent literature. *Am. J. Clin. Pathol.* 39:167-174.
22. de la Camara, R., I. Pinilla, E. Muñoz, B. Buendía, J. L. Steegmann, and J. M. Fernández-Rañada. 1996. *Penicillium brevicompactum* as the cause of a necrotic lung ball in an allogeneic bone marrow transplant recipient. *Bone Marrow Transplant.* 18:1189-1193.
23. Atalay, A., A. N. Koc, G. Akyol, N. Cakir, L. Kaynar, and A. Ulu-Kilic. 2016. Pulmonary infection caused by *Talaromyces purpurogenus* in a patient with multiple myeloma. *Infez. Med.* 24:153-157.
24. Successful treatment of pulmonary invasive fungal infection by *Penicillium nonmarneffei* in lymphoblastic lymphoma: case report and literature review. *Label Ramirez* 1,2, Alicia Hidron 1,3 & Ricardo Cardona 25. Geltner, C., C. Lass-Floer, H. Bonatti, L. Müller, and I. Stelzmueller. 2013. Invasive pulmonary mycosis due to *Penicillium chrysogenum*: a new invasive pathogen. *Transplantation* 95:e21-e23.
26. Swoboda-Kopec, E., M. M. Wroblewska, A. Rokosz, and M. Luczak. 2003. Mixed bloodstream infection with *Staphylococcus aureus* and *Penicillium chrysogenum* in an immunocompromised patient: case report and review of the literature. *Clin. Microbiol. Infect.* 9:1116-1117.
27. Ghannoum, M. A., R. J. Jurevic, P. K. Mukherjee, F. Cui, M. Sikaroodi, A. Naqvi, et al. 2010. Characterization of the oral fungal microbiome (mycobiome) in healthy individuals. *PLoS Pathog.* 6:e1000713.
28. Guevara-Suarez, M., D. A. Sutton, J. F. Cano-Lira, D. Garcia, A. Martin-Vicente, N. Wiederhold, et al. 2016. *Penicillium*-like fungi from clinical samples in the USA and their antifungal susceptibility. *J. Clin. Microbiol.* 54:2155-2161. ©2018 The Authors. *Clinical Case Reports* published by John Wiley & Sons Ltd. 11571. Ramirez et al. *Penicilliosis and immunosuppression*.